Stock Track | BIOCYTOGEN-B Soars 9.18% in Early Trading on Strong Q1 Earnings and Major R&D Investment

Stock Track04-28

BIOCYTOGEN-B's stock price soared 9.18% during early trading on Tuesday, reflecting strong investor sentiment towards the company.

The surge follows the release of the company's first-quarter 2026 financial results, which showed remarkable growth. Revenue reached RMB 433 million, representing a 73.68% year-on-year increase, while net profit attributable to shareholders surged 885.41% to RMB 104 million. The company attributed this significant revenue growth primarily to increased demand for its core pharmacological efficacy services.

Further bolstering investor confidence was the company's announcement of a substantial capital investment plan. BIOCYTOGEN-B plans to invest approximately RMB 1.6 billion through a subsidiary to construct a comprehensive model animal and antibody drug research and development base, signaling a strong commitment to future growth and expansion in its specialized biotech fields.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150363873?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 09:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150363873","market":"us","top_or_hot":-1,"title":"Stock Track | BIOCYTOGEN-B Soars 9.18% in Early Trading on Strong Q1 Earnings and Major R&D Investment","media":"Stock Track","content":"<p>BIOCYTOGEN-B's stock price soared 9.18% during early trading on Tuesday, reflecting strong investor sentiment towards the company.</p><p>The surge follows the release of the company's first-quarter 2026 financial results, which showed remarkable growth. Revenue reached RMB 433 million, representing a 73.68% year-on-year increase, while net profit attributable to shareholders surged 885.41% to RMB 104 million. The company attributed this significant revenue growth primarily to increased demand for its core pharmacological efficacy services.</p><p>Further bolstering investor confidence was the company's announcement of a substantial capital investment plan. BIOCYTOGEN-B plans to invest approximately RMB 1.6 billion through a subsidiary to construct a comprehensive model animal and antibody drug research and development base, signaling a strong commitment to future growth and expansion in its specialized biotech fields.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BIOCYTOGEN-B Soars 9.18% in Early Trading on Strong Q1 Earnings and Major R&D Investment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BIOCYTOGEN-B Soars 9.18% in Early Trading on Strong Q1 Earnings and Major R&D Investment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-28 09:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B's stock price soared 9.18% during early trading on Tuesday, reflecting strong investor sentiment towards the company.</p><p>The surge follows the release of the company's first-quarter 2026 financial results, which showed remarkable growth. Revenue reached RMB 433 million, representing a 73.68% year-on-year increase, while net profit attributable to shareholders surged 885.41% to RMB 104 million. The company attributed this significant revenue growth primarily to increased demand for its core pharmacological efficacy services.</p><p>Further bolstering investor confidence was the company's announcement of a substantial capital investment plan. BIOCYTOGEN-B plans to invest approximately RMB 1.6 billion through a subsidiary to construct a comprehensive model animal and antibody drug research and development base, signaling a strong commitment to future growth and expansion in its specialized biotech fields.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1150363873","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150363873","pubTimestamp":1777341555,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BIOCYTOGEN-B's stock price soared 9.18% during early trading on Tuesday, reflecting strong investor sentiment towards the company.The surge follows the release of the company's first-quarter 2026...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"个股赛道|百奥赛图-B早盘大涨9.18%因Q1盈利强劲及重大研发投入","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"BIOCYTOGEN-B's stock price soared 9.18% during early trading on Tuesday, reflecting strong investor sentiment towards the company.The surge follows the release of the company's first-quarter 2026 financial results, which showed remarkable growth. Revenue reached RMB 433 million, representing a 73.68% year-on-year increase, while net profit attributable to shareholders surged 885.41% to RMB 104 million. The company attributed this significant revenue growth primarily to increased demand for its core pharmacological efficacy services.Further bolstering investor confidence was the company's announcement of a substantial capital investment plan. BIOCYTOGEN-B plans to invest approximately RMB 1.6 billion through a subsidiary to construct a comprehensive model animal and antibody drug research and development base, signaling a strong commitment to future growth and expansion in its specialized biotech fields.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150363873","isCrawlerRequest":true}